权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Consortium for Viral Systems Biology (CViSB)

病毒系统生物学联盟 (CViSB)

基本信息

批准号：
10469781
负责人：
Kristian Graugaard Andersen
金额：
$ 59.71万
依托单位：
SCRIPPS RESEARCH INSTITUTE, THE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-07 至 2023-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10469781
关键词：
Address Affect Africa Binding Biological Case Fatality Rates Cessation of life Clinical Communities Computational algorithm Country Data Set Development Disease Disease Marker Disease Outbreaks Ebola Ebola Hemorrhagic Fever Ebola virus Epidemic Future Genetic Goals Healthcare Hospitals Human Immunologics Immunotherapeutic agent Individual Infection Infrastructure Integration Host Factors Investigation Lassa Fever Lassa virus Lead Measurement Medicine Mission Molecular Outcome Outcomes Research Patient-Focused Outcomes Patients Physiological Play Research Research Infrastructure Resistance Role Severities Statistical Models Survivors Symptoms System Systems Biology Technology Vaccines Viral Viral Hemorrhagic Fevers Virus Work cohort data access data tools fighting human disease human pathogen innovation insight large scale data member microbial neutralizing antibody novel pathogen personalized medicine predictive marker predictive modeling programs response treatment strategy

项目摘要

Project Summary/Abstract The Ebola epidemic that ravaged West Africa from 2013 to 2016 is by far the largest outbreak ever recorded. Weak healthcare infrastructure, community resistance, and a slow uncoordinated response, allowed the epidemic to spin out of control. The region, however, is no stranger to dealing with viral hemorrhagic fevers. Lassa fever is caused by infection with Lassa virus and is hyper-endemic in West Africa. Lassa fever is similar to Ebola in that infection with Lassa virus can lead to a severe hemorrhagic fever. Infections with both Lassa virus and Ebola virus can lead to deaths in more than 70% of hospitalized patients. It is estimated that tens of thousands of people die from Lassa fever each year. These numbers are likely underestimates, as the healthcare infrastructure in the aﬀected countries is extremely weak, surveillance almost non-existent, and most patients never present in the hospital. Despite the high case fatality rates of hospitalized Ebola and Lassa fever patients, however, some people appear to be able to quickly ﬁght the viruses, whereas others die quickly from infection. Yet, what distinguishes fatal from non-fatal disease and the development of symptomatic versus asymptomatic infection, remain largely unknown and severely understudied. The goal of the Consortium for Viral Systems Biology is to uncover the virus and human factors that determine how infected individuals are able to better ﬁght the viruses. We will achieve this goal by investigating the following three broad aims: Aim 1. Deﬁne virus and host factors responsible for survival and non-survival in Ebola and Lassa fever patients. Aim 2. Identify factors that play roles in the development of severe long-term symptoms in survivors. Aim 3. Deﬁne factors that determine whether human individuals develop symptomatic or asymptomatic disease. We will accomplish these aims by applying several ‘omics’ technologies, physiological measurements, and high-throughput experimental approaches to unique patient and survivor cohorts of Lassa fever and Ebola. We will develop novel predictive statistical models for identifying critical disease correlates and analyze large-scale data sets to pinpoint causal host-pathogen interactions. By elucidation the molecular networks that play critical roles in patient outcomes, this research will allow us to identify new targets for medicines and vaccines and inform personalized treatment strategies. Our study will also provide novel research frameworks and computational algorithms applicable to a wide range of other human pathogens.

项目总结/文摘